Vice versa, it would be interesting to evaluate whether ARTC2-deficient OT-I T cells are less potent in killing OVA-expressing B16 melanoma, as CD73 activity would not be dampened by NAD+ in the tumor environment. This evidence concerns the gene NT5E and neoplasm.